Placeholder Banner

BIO Applauds USDA-FDA Agreement to Improve Coordination

January 30, 2018

Specifically, the agreement references the recently released Agricultural and Rural Prosperity Task Force’s Report and says “USDA and FDA are committed to modernizing the Coordinated Framework for the Regulation of Biotechnology and the U.S. agricultural biotechnology regulatory system to develop efficient, science-based regulatory practices for products of biotechnology by working in partnership with other federal agencies on the corresponding National Strategy for Modernizing the Regulatory Systems for Biotechnology Products.”

“BIO applauds the agreement and supports the broad recommendation to enhance coordination between the agencies governing the use of products using agricultural biotechnology,” said Dana O'Brien, BIO’s Executive Vice President for Food & Agriculture. “BIO has long supported a more harmonized Coordinated Framework for science-based regulation, especially in regard to the treatment of future products such as gene edited innovations.”

O’Brien echoed many of the proposals contained in the Task Force report and the National Strategy and said BIO looks forward to engaging with the Administration on implementation.

“We need national policies that recognize the importance of science and technology and encourage continued investment,” O’Brien said. “This agreement is another step forward towards a system that promotes ag innovation, economic growth, competitiveness and job creation in America’s thriving biotechnology sector.”

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…